SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a relatively novel class of oral anti-diabetic agents, have been approved and used in multiple countries as glucose-lowering agents in type 2 diabetes patients as an adjunct to diet and exercise.